Find trials
Search tips

Rheumatoid Arthritis Patients in Sustained Remission Biorepository

Overview

About this study

The purpose of this study is to create a biorepository of biosamples from patients with rheumatoid arthritis (RA) in sustained remission. Identifying biomarkers associated with failure vs success of immunosuppressive treatments (DMARD) tapering is a critical need which will allow to maximize the benefits and safety of available treatments.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • All patients with rheumatoid arthritis (RA) diagnosed after 1995:
    • Diagnosis defined as a clinical diagnosis by a rheumatologist.
  • Sustained remission (> 6 months) SDAI < 3.3 + normal CRP and no swollen joints.
  • Stable DMARD regimen for > 6 months (bDMARD, csDMARD or combination).
  • Decision to taper DMARDs by physician and patient.

Exclusion Criteria:

  • No Glucocorticoid use at inclusion.

Eligibility last updated 7/19/22. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Elena Myasoedova, M.D., Ph.D.

Open for enrollment

Contact information:

Patricia Kennedy

(507) 266-1986

Kennedy.Patricia1@mayo.edu

More information

Publications

Publications are currently not available

More about research at Mayo Clinic

.
CLS-20554037

Mayo Clinic Footer